Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia : A retrospective case-control study
Zsófia Klára Németh, Anna Szűcs, József Vitrai, Dóra Juhász, János Pál Németh, Dr András Holló
Ideggyógyászati szemle, doi:10.18071/isz.74.0389
Az alábbi dokumentumot magáncélra töltötték le az eLitMed.hu webportálról. A dokumentum felhasználása a szerzôi jog szabályozása alá esik. Kulcsszavak: fluoxetin, COVID-19, SARS-CoV-2, pneumonia, túlélés, mortalitás score did not show statistical difference between the fluoxetine and non-fluoxetine groups supporting the reliability of our finding. Conclusion -Provisional to confirmation in randomised controlled studies, fluoxetine may be a potent treatment increasing the survival for COVID-19 pneumonia.
References
Baldwin, Woods, Lawson, Taylor, Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis, BMJ,
doi:10.1136/bmj.d1199
Brambilla, Cipriani, Hotopf, Barbui, Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data, Pharmacopsychiatry,
doi:10.1055/s-2005-837806
Carpinteiro, Edwards, Hoffmann, Kochs, Gripp et al., Pharmacological inhibition of acid sphin gomyelinase prevents uptake of SARS-CoV-2 by epithelial cells, Cell Rep Med,
doi:10.1016/j.xcrm.2020.100142
Colombo, Colombo, Maves, Performance analysis of the national early warning score and modified early warning score in the adaptive COVID-19 Treatment Trial Cohort, Crit Care Explor
Creeden, Imami, Eby, Gillman, Becker et al., Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection, Biomed Pharmacother,
doi:10.1016/j.biopha.2021.111437
Doupnik, Mitra, Feudtner, Marcus, The Influence of Comorbid Mood and Anxiety Disorders on Outcomes of Pediatric Patients Hospitalized for Pneumonia, Hosp Pediatr,
doi:10.1542/hpeds.2015-0177
Ely, Dittus, Girard, Point: should benzodiazepines be avoided in mechanically ventilated patients? Yes, Chest,
doi:10.1378/chest.12-1189
Fred, Kuivanen, Ugurlu, Casarotto, Levanov et al., Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine show antiviral activity against the novel variants in vitro, bioRxiv,
doi:10.1101/2021.03.22.436379
Glebov, Low-dose fluvoxamine modulates endocytic trafficking of SARS-CoV-2 spike protein: a potential mechanism for anti-COVID-19 protection by antidepressants, bioRxiv,
doi:10.1101/2021.06.15.448391
Gordon, Hiatt, Bouhaddou, Rezelj, Ulferts et al., Comparative host-coronavirus protein inter action networks reveal pan-viral disease mechanisms, Science,
doi:10.1126/science.abe9403
Hashimoto, Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor, Eur Arch Psychiatry Clin Neurosci,
doi:10.1007/s00406-020-01231-x
Hiles, Baker, De Malmanche, Attia, Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis, Psychol Med,
doi:10.1017/S0033291712000128
Hoertel, Sánchez-Rico, Vernet, Beeker, Jannot et al., Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study, Mol Psychiatry,
doi:10.1038/s41380-021-01021-4
Jakubovski, Johnson, Nasir, Müller-Vahl, Bloch, Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders, Depress Anxiety,
doi:10.1002/da.22854
Laporte, Chapelle, Caillet, Beyens, Bellet et al., Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies, Pharmacol Res,
doi:10.1016/j.phrs.2016.08.017
Larici, Cicchetti, Marano, Bonomo, Storto, COVID-19 pneumonia: current evidence of chest imaging features, evolution and prognosis, Chin J Acad Radiol,
doi:10.1007/s42058-021-00068-0
Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2020.22760
Lundström, Isaksson, Näsman, Wester, Mår Tensson et al., Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial, Lancet Neurol,
doi:10.1016/S1474-4422(20)30219-2
Obiora, Hubbard, Sanders, Myles, The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort, Thorax,
doi:10.1136/thoraxjnl-2012-202374
Pérez-Cano, Moreno-Murguía, Morales-López, Crow-Buchanan, English et al., Anxiety, depression, and stress in response to the coronavirus disease-19 pandemic, Cir,
doi:10.24875/CIRU.20000561
Rosen, Seki, Fernández-Castañeda, Beiter, Eccles et al., Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis, Sci Transl Med,
doi:10.1126/scitranslmed.aau5266
Samuel, Seifert, Risk of bleeding in patients on fulldose enoxaparin with venous thromboembolism and selective serotonin reuptake inhibitors, Ann Pharmacother,
doi:10.1177/1060028016677309
Schloer, Brunotte, Goretzko, Mecate-Zambrano, Korthals et al., Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine, Emerg Microbes Infect,
doi:10.1080/22221751.2020.1829082
Schloer, Brunotte, Mecate-Zambrano, Zheng, Tang et al., Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro, Br J Pharmacol,
doi:10.1111/bph.15418
Sed, El-Khouly, Bar, Am, Ghorab, Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection, Pharmaceutics,
doi:10.1016/j.ijpharm.2021.121023
Starke, Reissig, Petereit-Haack, Schmauder, Nienhaus et al., The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis, medRxiv,
doi:10.1101/2021.05.27.21257909
Sukhatme, Reiersen, Vayttaden, Sukhatme, Flu voxamine: a review of its mechanism of action and its role in COVID-19, Front Pharmacol,
doi:10.3389/fphar.2021.652688
Sultana, Crisafulli, Gabbay, Lynn, Shakir et al., Challenges for drug repurposing in the COVID-19 pandemic era, Front Pharmacol,
doi:10.3389/fphar.2020.588654
Taylor, Freemantle, Geddes, Bhagwagar, Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis, Arch Gen Psychiatry,
doi:10.1001/archpsyc.63.11.1217
Vai, Mazza, Colli, Foiselle, Allen et al., Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis, Lancet Psychiatry,
doi:10.1016/S2215-0366(21)00232-7
Wang, Li, Shi, Que, Liu et al., Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies, Mol Psychiatry,
doi:10.1038/s41380-019-0595-x
Watkins, Koch, Sherwood, Blumenthal, Davidson et al., Association of anxiety and depression with all-cause mortality in individuals with coronary heart disease, J Am Heart Assoc,
doi:10.1161/JAHA.112.000068
Zimniak, Kirschner, Hilpert, Geiger, Danov et al., The serotonin reuptake inhibitor fluoxetine inhibits SARS-CoV-2 in human lung tissue, Sci Rep,
doi:10.1038/s41598-021-85049-0
Çağlar, Kaçer, Anxiety levels in patients admitted to the emergency department with myocardial infarction or COVID-19 pneumonia, Psychol Health Med,
doi:10.1080/13548506.2021